|
[1]
|
Mohammadi, M. and Hedayati, M. (2017) A Brief Review on The Molecular Basis of Medullary Tyroid Carcinoma. Cell Journal, 18, 485-492.
|
|
[2]
|
东彦, 赵建宏. 降钙素原检测及临床应用评价[J]. 临床荟萃, 2017, 32(4): 284-286, 290.
|
|
[3]
|
Amin, M.B., Edge, S.B., Greene, F.L., et al. (2017) AJCC Cancer Staging Manual. 8th Edition, Springer, New York. [Google Scholar] [CrossRef]
|
|
[4]
|
Wells, S.A., Asa, S.L., Dralle, H., et al. (2015) Revised American Thyroid Association Guidelines for the Management of Medullary Thyroid Carcinoma. Thyroid, 25, 567-610. [Google Scholar] [CrossRef] [PubMed]
|
|
[5]
|
王宇, 渠宁, 史潇, 等. 甲状腺髓样癌诊治现状及热点问题思考[J]. 肿瘤预防与治疗, 2019, 32(6): 475-479.
|
|
[6]
|
Rink, T., Truong, P.N., Schroth, H.J., et al. (2009) Calculation and Validation of a Plasma Calcitonin Limit for Early Detection of Medulary Thyroid Carcinoma in Nodular Thyroid Disease. Thyroid, 19, 327-332. [Google Scholar] [CrossRef] [PubMed]
|
|
[7]
|
Scheuba, C., Kaserer, K., Moritz, A., et al. (2009) Sporadic Hypercalcitoninemia: Clinical and Therapeutic Consequences. Endocrine-Related Cancer, 16, 243-253. [Google Scholar] [CrossRef]
|
|
[8]
|
Kloos, R.T., Eng, C., Evans, D.B., et al. (2009) Medulary Thyroid Cancer: Management Guidelines of the American Thyroid Association. Thyroid, 19, 565-612. [Google Scholar] [CrossRef] [PubMed]
|
|
[9]
|
Hajje, G., Borget, I., Leboulleux, S., et al. (2012) Early Changes in Carcinoembryonic Antigen But Not in Calcitonin Levels Are Correlated with the Progression-Free Survival in Medullary Thyroid Carcinoma Patients Treated with Cytotoxic Chemotherapy. European Journal of Endocrinology, 168, 113-118. [Google Scholar] [CrossRef]
|
|
[10]
|
Barbet, J., Campion, L., et al. (2005) Prognostic Impact of Serum Calcitonin and Carcinoembryonic Antigen Doubling-Times in Patients with Medullary Thyroid Carcinoma. The Journal of Clinical Endocrinology & Metabolism, 90, 6077-6084. [Google Scholar] [CrossRef] [PubMed]
|
|
[11]
|
Saltiki, K., Rentziou, G., Stamatelopoulos, K., et al. (2014) Small Medullary Thyroid Carcinoma: Post-Operative Calcitonin Rather than Tumour Size Predicts Disease Persistence and Progression. European Journal of Endocrinology, 171, 117-126. [Google Scholar] [CrossRef]
|
|
[12]
|
Machens, A. and Dralle, H. (2010) Biomarker-Based Risk Stratification for Previously Untreated Medullary Thyroid Cancer. The Journal of Clinical Endocrinology & Metabolism, 95, 2655-2663. [Google Scholar] [CrossRef] [PubMed]
|
|
[13]
|
Guesgen, C., Willms, A., Zwad, A., et al. (2013) Investigation of Factors Potentially Influencing Calcitonin Levels in the Screening and Follow-Up for Medullary Thyroid Carcinoma: A Cautionary Note. BMC Clinical Pathology, 13, 27-34. [Google Scholar] [CrossRef] [PubMed]
|
|
[14]
|
Brutsaert, E.F., Gersten, A.J., Tassler, A.B., et al. (2015) Medullary Thyroid Cancer with Undetectable Serum Calcitonin. The Journal of Clinical Endocrinology & Metabolism, 100, 337-341. [Google Scholar] [CrossRef] [PubMed]
|
|
[15]
|
Boschin, I.M., Torresan, F., Toniato, A., et al. (2014) Incidental Medullary Thyroid Microcarcinoma Revealed by Mild Increase of Preoperative Serum Calcitonin Levels: Therapeutic Implications. Endocrine, 45, 448-453. [Google Scholar] [CrossRef] [PubMed]
|
|
[16]
|
Trimboli, P., Seregni, E., Treglia, G., et al. (2015) Procalcitonin for Detecting Medullary Thyroid Carcinoma: A Systematic Review. Endocrine-Related Cancer, 22, 157-164. [Google Scholar] [CrossRef]
|
|
[17]
|
Trimboli, P., Guidobaldi, L., Bongiovanni, M., et al. (2016) Use of Fine-Needle Aspirate Calcitonin to Detect Medullary Thyroid Carcinoma: A Systematic Review. Diagnostic Cytopathology, 44, 45-51. [Google Scholar] [CrossRef] [PubMed]
|
|
[18]
|
Giovanella, L., Crippa, S. and Cariani, L. (2008) Serum Calcitonin-Negative Medulary Thyroid Carcinoma: Role of CgA and CEA as Complementary Markers. The International Journal of Biological Markers, 23, 129-131. [Google Scholar] [CrossRef]
|
|
[19]
|
江荷, 江小林, 姜勇, 等. 降钙素阴性的甲状腺神经内分泌肿瘤临床病理特征分析[J]. 西部医学, 2018, 30(4): 498-502.
|